211 related articles for article (PubMed ID: 30075155)
1. Concordance levels of PD-L1 expression by immunohistochemistry, mRNA in situ hybridization, and outcome in lung carcinomas.
Coppock JD; Volaric AK; Mills AM; Gru AA
Hum Pathol; 2018 Dec; 82():282-288. PubMed ID: 30075155
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer.
Yu H; Batenchuk C; Badzio A; Boyle TA; Czapiewski P; Chan DC; Lu X; Gao D; Ellison K; Kowalewski AA; Rivard CJ; Dziadziuszko R; Zhou C; Hussein M; Richards D; Wilks S; Monte M; Edenfield W; Goldschmidt J; Page R; Ulrich B; Waterhouse D; Close S; Jassem J; Kulig K; Hirsch FR
J Thorac Oncol; 2017 Jan; 12(1):110-120. PubMed ID: 27639678
[TBL] [Abstract][Full Text] [Related]
3. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
[TBL] [Abstract][Full Text] [Related]
4. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH
Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662
[TBL] [Abstract][Full Text] [Related]
5. Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer.
Sepesi B; Cuentas EP; Canales JR; Behrens C; Correa AM; Vaporciyan A; Weissferdt A; Kalhor N; Moran C; Swisher S; Wistuba I
Semin Thorac Cardiovasc Surg; 2017 Autumn; 29(3):408-415. PubMed ID: 29195578
[TBL] [Abstract][Full Text] [Related]
6. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
Büttner R; Gosney JR; Skov BG; Adam J; Motoi N; Bloom KJ; Dietel M; Longshore JW; López-Ríos F; Penault-Llorca F; Viale G; Wotherspoon AC; Kerr KM; Tsao MS
J Clin Oncol; 2017 Dec; 35(34):3867-3876. PubMed ID: 29053400
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 expression in lung adenosquamous carcinomas compared with the more common variants of non-small cell lung cancer.
Shi X; Wu S; Sun J; Liu Y; Zeng X; Liang Z
Sci Rep; 2017 Apr; 7():46209. PubMed ID: 28387300
[TBL] [Abstract][Full Text] [Related]
8. Comparison of
Erber R; Stöhr R; Herlein S; Giedl C; Rieker RJ; Fuchs F; Ficker JH; Hartmann A; Veltrup E; Wirtz RM; Brueckl WM
Anticancer Res; 2017 Dec; 37(12):6771-6778. PubMed ID: 29187455
[TBL] [Abstract][Full Text] [Related]
9. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.
McLaughlin J; Han G; Schalper KA; Carvajal-Hausdorf D; Pelekanou V; Rehman J; Velcheti V; Herbst R; LoRusso P; Rimm DL
JAMA Oncol; 2016 Jan; 2(1):46-54. PubMed ID: 26562159
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.
Brody R; Zhang Y; Ballas M; Siddiqui MK; Gupta P; Barker C; Midha A; Walker J
Lung Cancer; 2017 Oct; 112():200-215. PubMed ID: 29191596
[TBL] [Abstract][Full Text] [Related]
11. Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1).
Shimoji M; Shimizu S; Sato K; Suda K; Kobayashi Y; Tomizawa K; Takemoto T; Mitsudomi T
Lung Cancer; 2016 Aug; 98():69-75. PubMed ID: 27393509
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
[TBL] [Abstract][Full Text] [Related]
13. Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer.
Sheffield BS; Fulton R; Kalloger SE; Milne K; Geller G; Jones M; Jacquemont C; Zachara S; Zhao E; Pleasance E; Laskin J; Jones SJ; Marra MA; Yip S; Nelson BH; Gown AM; Ho C; Ionescu DN
J Histochem Cytochem; 2016 Oct; 64(10):587-600. PubMed ID: 27591097
[TBL] [Abstract][Full Text] [Related]
14. Assessment of PD-L1 mRNA and protein expression in non-small cell lung cancer, head and neck squamous cell carcinoma and urothelial carcinoma tissue specimens using RNAScope and immunohistochemistry.
Duncan DJ; Scott M; Scorer P; Barker C
PLoS One; 2019; 14(4):e0215393. PubMed ID: 30986253
[TBL] [Abstract][Full Text] [Related]
15. Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer.
Lafuente-Sanchis A; Zúñiga Á; Estors M; Martínez-Hernández NJ; Cremades A; Cuenca M; Galbis JM
Clin Lung Cancer; 2017 Mar; 18(2):e109-e116. PubMed ID: 27816393
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer.
Tsao MS; Le Teuff G; Shepherd FA; Landais C; Hainaut P; Filipits M; Pirker R; Le Chevalier T; Graziano S; Kratze R; Soria JC; Pignon JP; Seymour L; Brambilla E
Ann Oncol; 2017 Apr; 28(4):882-889. PubMed ID: 28137741
[TBL] [Abstract][Full Text] [Related]
17. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
[TBL] [Abstract][Full Text] [Related]
18. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
Heymann JJ; Bulman WA; Swinarski D; Pagan CA; Crapanzano JP; Haghighi M; Fazlollahi L; Stoopler MB; Sonett JR; Sacher AG; Shu CA; Rizvi NA; Saqi A
Cancer Cytopathol; 2017 Dec; 125(12):896-907. PubMed ID: 29024471
[TBL] [Abstract][Full Text] [Related]
20. [PD-L1 testing in non-small cell lung carcinoma: Guidelines from the PATTERN group of thoracic pathologists].
Lantuejoul S; Adam J; Girard N; Duruisseaux M; Mansuet-Lupo A; Cazes A; Rouquette I; Gibault L; Garcia S; Antoine M; Vignaud JM; Galateau-Sallé F; Sagan C; Badoual C; Penault-Llorca F; Damotte D;
Ann Pathol; 2018 Apr; 38(2):110-125. PubMed ID: 29571563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]